PsA Treatment Options Expand
Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.
By
Kathryn Wighton
March 9, 2026
Clinical Scorecard: PsA Treatment Options Expand
At a Glance
Category Detail
Condition Active Psoriatic Arthritis (PsA) Key Mechanisms Deucravacitinib is a selective TYK2 inhibitor targeting interleukin-23, interleukin-12, and type 1 interferon pathways. Target Population Adults aged 18 years or older with active PsA and a history of plaque psoriasis. Care Setting Multicenter, randomized, double-blind, placebo-controlled clinical trials.
Key Highlights
Deucravacitinib is the first TYK2 inhibitor approved for PsA. Improved ACR20 response rates: 54% vs 34% (POETYK PsA-1) and 54% vs 39% (POETYK PsA-2). ACR50 and ACR70 responses also favored deucravacitinib. Minimal disease activity achieved by a greater proportion of patients on deucravacitinib. Safety profile consistent with previous studies in plaque psoriasis. Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical criteria including swollen and tender joints, and history of plaque psoriasis. Management
Consider deucravacitinib for adults with active PsA, especially those with prior TNF inhibitor exposure. Monitoring & Follow-up
Monitor for common adverse reactions such as upper respiratory infections and increased creatine phosphokinase. Risks
Potential adverse reactions include herpes simplex, mouth ulcers, folliculitis, and acne. Patient & Prescribing Data
Adults with active PsA, including those with prior TNF inhibitor exposure.
Deucravacitinib is administered once daily at a dose of 6 mg.
Clinical Best Practices
Utilize ACR20 criteria for assessing treatment response. Consider patient history of biologic DMARDs when prescribing. References
